Novavax, Inc.
https://novavax.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Novavax, Inc.
Claims Stream In Under COVAX No-Fault Compensation Program
The WHO indicates that several claim applications have been made under the COVAX no-fault lump-sum compensation program for COVID-19 vaccines. It remains to be seen how the scheme may apply to countries like India, which is also expected to take a call on indemnity to vaccine makers.
Deal Watch: Pfizer Invests In Spero, Parexel Trades Hands
EQT and Goldman Sachs to pay $8.5bn in Parexel’s second private equity buyout in four years.
CureVac Still Hopes Variants Could Win Favor For COVID-19 Vaccine
Patients 18-60 had a protection rate of 53%, but there were too few cases among those older than 60 – a crucial subgroup – in HERALD to draw conclusions about the vaccine’s efficacy among older people.
Vaccines Show Signs Of Efficacy Against Delta Variant, But Is It Enough?
AstraZeneca and Moderna disclosed clinical and preclinical evidence that their COVID-19 vaccines, Vaxzevria and mRNA-1273, provide protection against the B.1.617.2 strain.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
- Vaccines
-
Biotechnology
- Liposomes
- Other Names / Subsidiaries
-
- CPL Biologicals Pvt. Ltd. (Joint Venture with Cadila)
- Isconova AB
- Novavax AB